Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis.

Fiche publication

Date publication

août 2021




Membres identifiés du Cancéropôle Est :
Pr KOHLI Evelyne

Tous les auteurs :
Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E


Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a low-dose combination therapy of methotrexate and adalimumab, shortly before vaccine administration. Both near-normal and impaired immune responses to vaccines have been reported previously in patients treated with these drugs. Our case report shows that, even at low doses, combined methotrexate-adalimumab therapy can be associated with a weak immune response to the mRNA1273 vaccine in elderly patients.

Mots clés

SARS-CoV-2, adalimumab, antibody response, mRNA1273 vaccine, methotrexate


Vaccines (Basel). 2021 Aug 9;9(8):